Report for Q1 2026
Filed with SSE · · 12 pages · Chinese
Zhejiang Shapuaisi Pharmaceutical Co. Ltd. on 6ix
Earlier from Zhejiang Shapuaisi Pharmaceutical
- Indicative Announcement on Convening the 2025 Annual General Meeting
- Announcement on Postponing Reply to Letter of Inquiry from SSE
- Announcement on the Remuneration Plan for Directors and Senior Management Members in 2026
- Announcement on Receipt of the "Letter of Shareholder Suggestions" from the China Securities Investor Services Center
- Announcement on Receiving Letter of Supervision and Inquiry Regarding Related-Party Asset Purchase of Zhejiang Shapuaisi Pharmaceutical Co., Ltd. from Shanghai Stock Exchange
Later from Zhejiang Shapuaisi Pharmaceutical
- Announcement on Proposed Termination of Acquisition of 100% Equity in Shanghai Qinli Industrial Co., Ltd. and Related Party Transactions
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Obtaining Drug Registration Certificate for Sildenafil Citrate Orally Disintegrating Tablets
- Announcement on Release of Pledge of Shares by Actual Controller
- Announcement on Obtaining the "Drug Registration Certificate" for Vitamin B12 Eye Drops
Follow Zhejiang Shapuaisi Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Shapuaisi Pharmaceutical